RECURRENT MEDULLOBLASTOMA

This study is testing an oral medication called tipifarnib in children and young adults (ages 1-21) whose advanced solid tumors, lymphoma, or histiocytic disorders have a specific genetic change in a gene called HRAS. The goal is to see if the drug can shrink tumors and control t…

This study is testing a new combination treatment for children and young adults whose medulloblastoma or ependymoma brain tumors have come back. The main goal is to see if adding a targeted radiation treatment, delivered directly into the fluid-filled spaces of the brain, can hel…

This study is testing how well a drug called selpercatinib works for children and young adults with advanced or hard-to-treat cancers that have a specific genetic change in the RET gene. The drug is designed to block the growth of cancer cells with this change. Participants take …

This study is testing a drug called larotrectinib in children and young adults (ages 1-21) whose advanced solid tumors, lymphomas, or histiocytic disorders have returned or not responded to standard treatments. The drug is given to patients whose tumors have a specific genetic ch…

This early-stage trial is testing the safety and early effectiveness of a drug called pembrolizumab in children with aggressive brain tumors that have come back or stopped responding to standard treatments. The drug is an immunotherapy, which aims to help the body's own immune sy…

This study aimed to test the safety of delivering cancer drugs directly into a fluid-filled space in the brain (the fourth ventricle) for people with recurrent brain tumors like medulloblastoma and ependymoma. It planned to give an immunotherapy drug (nivolumab) combined with ano…

This study is testing a drug called ensartinib in children and young adults whose advanced cancers have specific genetic changes (ALK or ROS1). The goal is to see if the drug can shrink tumors or stop them from growing in patients whose cancer has come back or hasn't responded to…

This study is testing an oral drug called ulixertinib in children and adolescents whose advanced cancers have not responded to standard treatments and have a specific genetic change in a cell pathway called MAPK. The main goal is to see if the drug can shrink tumors and control t…

This study is testing a personalized approach for children and young adults with advanced cancers that have come back or stopped responding to standard treatments. Doctors first test the genetic makeup of a patient's tumor to look for specific changes. If a matching change is fou…

This study is testing a drug called ivosidenib in children and young adults (ages 1-21) whose cancers have returned or not responded to standard treatments. The drug is given as a daily pill and is designed to specifically block cancer growth in tumors that have a particular gene…